BCAB - CIK 0001826892
BioAtla, Inc. trades as BCAB. This page tracks BioAtla, Inc. through 490 SEC filings, with financial statements and metrics updated as new reports are filed.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-15 |
| Annual report (amended) | 10-K/A | 2026-04-29 |
| Major company event | 8-K | 2026-04-02 |
| Major company event | 8-K | 2026-03-31 |
| Annual report | 10-K | 2026-03-31 |
| Employee stock plan | S-8 | 2026-03-31 |
| Major company event | 8-K | 2026-03-23 |
| Prospectus supplement | 424B2 | 2026-03-20 |
The largest companies sharing BioAtla, Inc.'s SEC industry classification (biological products, (no diagnostic substances)).
In its latest fiscal year BioAtla, Inc. reported a net loss of $59.61M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.